2009
DOI: 10.1590/s0066-782x2009001300006
|View full text |Cite
|
Sign up to set email alerts
|

6. Fármacos cardiovasculares na gestação e amamentação

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 31 publications
0
0
0
Order By: Relevance
“…ACEIs are contraindicated during the second and third trimesters of pregnancy due to well-recognized congenital malformations, such as the renin-angiotensin-system (RAS) blockade syndrome [2,3]. Most part of guidelines and studies contraindicate ACEI use during the first trimester of pregnancy [5,6]. Nevertheless, actual risks are not fully cleared in literature, especially because hypertension represents an isolated risk factor for malformations, and in some of those studies the sample presented comorbidities such as diabetes, which were important confounding factor in the analysis of fetal outcomes risk [3,[7][8][9].…”
Section: Introductionmentioning
confidence: 99%
“…ACEIs are contraindicated during the second and third trimesters of pregnancy due to well-recognized congenital malformations, such as the renin-angiotensin-system (RAS) blockade syndrome [2,3]. Most part of guidelines and studies contraindicate ACEI use during the first trimester of pregnancy [5,6]. Nevertheless, actual risks are not fully cleared in literature, especially because hypertension represents an isolated risk factor for malformations, and in some of those studies the sample presented comorbidities such as diabetes, which were important confounding factor in the analysis of fetal outcomes risk [3,[7][8][9].…”
Section: Introductionmentioning
confidence: 99%